PALI vs. ME, RLMD, TRIB, SYBX, ERNA, MRKR, CLDI, RLYB, HOTH, and NXTC
Should you be buying Palisade Bio stock or one of its competitors? The main competitors of Palisade Bio include 23andMe (ME), Relmada Therapeutics (RLMD), Trinity Biotech (TRIB), Synlogic (SYBX), Eterna Therapeutics (ERNA), Marker Therapeutics (MRKR), Calidi Biotherapeutics (CLDI), Rallybio (RLYB), Hoth Therapeutics (HOTH), and NextCure (NXTC). These companies are all part of the "pharmaceutical products" industry.
Palisade Bio vs.
23andMe (NASDAQ:ME) and Palisade Bio (NASDAQ:PALI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, community ranking, institutional ownership and media sentiment.
23andMe has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, Palisade Bio has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500.
Palisade Bio has lower revenue, but higher earnings than 23andMe. Palisade Bio is trading at a lower price-to-earnings ratio than 23andMe, indicating that it is currently the more affordable of the two stocks.
In the previous week, 23andMe had 15 more articles in the media than Palisade Bio. MarketBeat recorded 19 mentions for 23andMe and 4 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.75 beat 23andMe's score of 0.04 indicating that Palisade Bio is being referred to more favorably in the news media.
23andMe received 1 more outperform votes than Palisade Bio when rated by MarketBeat users. However, 52.38% of users gave Palisade Bio an outperform vote while only 46.15% of users gave 23andMe an outperform vote.
Palisade Bio has a net margin of 0.00% compared to 23andMe's net margin of -183.39%. Palisade Bio's return on equity of -148.51% beat 23andMe's return on equity.
36.1% of 23andMe shares are owned by institutional investors. Comparatively, 11.8% of Palisade Bio shares are owned by institutional investors. 26.3% of 23andMe shares are owned by company insiders. Comparatively, 3.3% of Palisade Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Palisade Bio has a consensus price target of $12.00, indicating a potential upside of 1,486.25%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts clearly believe Palisade Bio is more favorable than 23andMe.
Summary
Palisade Bio beats 23andMe on 11 of the 18 factors compared between the two stocks.
Get Palisade Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for PALI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Palisade Bio Competitors List
Related Companies and Tools
This page (NASDAQ:PALI) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy PALI Stock Free PALI Stock Alerts